CMS Colorectal Cancer Drug Policy Will Not Limit Current Off-Label Coverage
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services releases its final national coverage determination for Avastin, Erbitux, Eloxatin and Camptosar. The final determination is in line with the draft NCD, covering off-label indications that are included in certain major compendia and are part of nine National Cancer Institute clinical trials.